Daily Ards Research Analysis
Today’s analysis identified a pilot observational study linking extracellular vesicle (EV) microRNA cargo to acute respiratory distress syndrome (ARDS) in sepsis. Distinct EV-miRNA signatures and bioinformatic enrichment of the GP6 signaling pathway suggest potential early biomarkers and mechanistic clues, warranting validation in larger cohorts.
Summary
Today’s analysis identified a pilot observational study linking extracellular vesicle (EV) microRNA cargo to acute respiratory distress syndrome (ARDS) in sepsis. Distinct EV-miRNA signatures and bioinformatic enrichment of the GP6 signaling pathway suggest potential early biomarkers and mechanistic clues, warranting validation in larger cohorts.
Research Themes
- Extracellular vesicles and exosomal miRNAs in ARDS
- Sepsis biomarker discovery and validation
- Pathophysiology linking EV cargo to lung injury (GP6 pathway)
Selected Articles
1. Circulating extracellular vesicles as potential biomarkers and mediators of acute respiratory distress syndrome in sepsis.
In a prospective two-timepoint analysis of septic patients with and without ARDS, plasma EVs (exosome-compatible) carried distinct miRNA cargo. Eight miRNAs were reduced (e.g., miR-766, miR-127, miR-340, miR-29b) and miR-885-5p increased in ARDS; paired analyses revealed group-specific temporal changes. Target enrichment implicated the GP6 signaling pathway, supporting EV-miRNAs as candidate biomarkers and mediators of lung inflammation in sepsis.
Impact: This pilot identifies a discrete EV-miRNA signature for sepsis-associated ARDS and nominates the GP6 pathway, providing a testable framework for biomarker development and mechanistic studies.
Clinical Implications: If validated, EV-miRNA panels could enable early risk stratification and monitoring for ARDS in sepsis and guide targeted investigations toward platelet-collagen/GP6 signaling modulation.
Key Findings
- Compared to sepsis without ARDS, sepsis+ARDS showed reduced EV levels of miR-766 (-35.7; p=0.002), miR-127 (-23.8; p=0.001), miR-340 (-13.5; p=0.006), miR-29b (-12.8; p=0.001), miR-744 (-7.1; p=0.05), miR-618 (-4.0; p=0.02), miR-598 (-3.8; p=0.035), and miR-1260 (-2.5; p=0.035), with increased miR-885-5p (9.5; p=0.028).
- Paired longitudinal analysis identified different sets of altered miRNAs in sepsis+ARDS (e.g., miR-1183, miR-1267, miR-1290, miR-17, miR-192, miR-199a-3p, miR-25, miR-485-3p, miR-518d, miR-720) versus sepsis only (e.g., miR-148a, miR-193a-5p, miR-199a-3p, miR-222, miR-25, miR-340, miR-744).
- Bioinformatic target analysis implicated the glycoprotein VI (GP6) signaling pathway in sepsis-associated ARDS based on the differentially expressed EV-miRNAs.
- Plasma-isolated EVs displayed characteristics compatible with exosomes, supporting their role as carriers of systemic inflammatory lung signals.
Methodological Strengths
- Prospective sampling at two standardized timepoints (24 hours and day 3) with paired analyses
- Targeted RT-qPCR profiling of 48 miRNAs in exosome-compatible EVs and group comparisons with effect sizes and p-values
- Exclusion of pulmonary-origin sepsis to reduce confounding of primary lung source
Limitations
- Small sample size (n=18; ARDS n=5) and single-center design limit generalizability
- No external validation cohort and uncertain multiple testing correction increase false-positive risk
- Lack of functional experiments to establish causality or confirm GP6 pathway involvement
- Limited linkage to clinical outcomes beyond ARDS presence and short follow-up
Future Directions: Validate EV-miRNA signatures in larger, multi-center prospective cohorts; apply stringent multiple-testing control and machine-learning classifiers; perform functional studies of candidate miRNAs and GP6 signaling in lung injury models; and integrate EV markers with clinical predictors for early ARDS risk stratification.
The early sequence of respiratory failure events after the onset of sepsis is still unknown. We hypothesize that the lung should signal through circulating extracellular vesicles (EVs) when it is affected by a systemic inflammatory response. Blood samples were obtained from septic patients with (n = 5) and without acute respiratory distress syndrome (ARDS) (n = 13) at 24 h of intensive care unit admission and 3 days later at Sírio-Libanês Hospital. Pulmonary-originated sepsis was not considered. The characteristics of the plasma-isolated EVs were compatible with exosomes. 48 miRNAs were evaluated by real-time PCR. Comparing all samples from patients with sepsis + ARDS to sepsis only, 9 miRNAs are transported in smaller amounts: miR-766 (-35.7, p = 0.002), miR-127 (-23.8, p = 0.001), miR-340 (-13.5, p = 0.006), miR-29b (-12.8, p = 0.001), miR-744 (-7.1, p = 0.05), miR-618 (-4.0, p = 0.02), miR-598 (-3.8, p = 0.035), miR-1260 (-2.5, p = 0.035); and miR-885-5p is expressed at higher levels (9.5; p = 0.028). In paired samples, the set of altered miRNAs is generally different (p < 0.05) between sepsis + ARDS (miR-1183,-1267,-1290,-17,-192,-199a-3p,-25,-485-3p,-518d,-720) or sepsis only (miR-148a,-193a-5p,-199a-3p,-222,-25,-340,744). Bioinformatic analysis showed that when sepsis is associated with ARDS, those differentially expressed miRNAs potentially target messenger RNAs from the Glycoprotein VI/GP6 signaling pathway. Circulating EV-miRNA cargo could be potential biomarkers of lung inflammation during sepsis in patients requiring mechanical ventilation.